三個皮匠報告
政策庫
new
付費
搜索

國產EGFR單抗生物類似藥管線進度（I/Ⅱ期及以上）-行業數據

國產EGFR單抗生物類似藥管線進度（I/Ⅱ期及以上）
國產EGFR單抗生物類似藥管線進度（I/Ⅱ期及以上）
（愛必妥®）聯合化療進行頭對頭的大樣本Ⅲ期臨床試驗（入組 688 例），且臨床數據顯示，A140 聯合化療方案，與西妥昔單抗注射液聯合化療相比，在客觀緩解率具有臨床等效性，且安全性相當，看好商業化潛力。
行業數據 下載Excel 下載圖片 原圖定位
圖片屬性
圖片格式：PNG 圖片大?。?45KB 圖片尺寸：2330*645
同報告圖片
 / 31
國產EGFR單抗生物類似藥管線進度（I/Ⅱ期及以上）_第1頁
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
國產EGFR單抗生物類似藥管線進度（I/Ⅱ期及以上）_第2頁
國產EGFR單抗生物類似藥管線進度（I/Ⅱ期及以上）_第3頁
國產EGFR單抗生物類似藥管線進度（I/Ⅱ期及以上）_第4頁
國產EGFR單抗生物類似藥管線進度（I/Ⅱ期及以上）_第5頁
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
國產EGFR單抗生物類似藥管線進度（I/Ⅱ期及以上）_第6頁
國產EGFR單抗生物類似藥管線進度（I/Ⅱ期及以上）_第7頁
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
國產EGFR單抗生物類似藥管線進度（I/Ⅱ期及以上）_第8頁
國產EGFR單抗生物類似藥管線進度（I/Ⅱ期及以上）_第9頁
fCDlubTku70gfCDlhajnkINOU0NMQ+WPkeeXheaVsO+8iOeZvuS4h+S+i++8iSB8IOS4reWbvU5TQ0xD5Y+R55eF5pWw77yI55m+5LiH5L6L77yJIHwKfC0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwKfCAyMDE3IHwgMS43ICAgICAgICAgICAgICAgICAgICAgIHwgMC43ICAgICAgICAgICAgICAgICAgICAgIHwKfCAyMDIyIHwgMi4wICAgICAgICAgICAgICAgICAgICAgIHwgMC44ICAgICAgICAgICAgICAgICAgICAgIHwKfCAyMDMwRXwgMi41ICAgICAgICAgICAgICAgICAgICAgIHwgMS4xICAgICAgICAgICAgICAgICAgICAgIHwKCui1hOaWmeadpea6kO+8muW8l+iLpeaWr+eJueaymeWIqeaWh++8jOWFrOWPuOaLm+iCoeivtOaYjuS5pu+8jOa1meWVhuivgeWIuOeglOeptuaJgA==
國產EGFR單抗生物類似藥管線進度（I/Ⅱ期及以上）_第10頁
國產EGFR單抗生物類似藥管線進度（I/Ⅱ期及以上）_第11頁
國產EGFR單抗生物類似藥管線進度（I/Ⅱ期及以上）_第12頁
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
國產EGFR單抗生物類似藥管線進度（I/Ⅱ期及以上）_第13頁
國產EGFR單抗生物類似藥管線進度（I/Ⅱ期及以上）_第14頁
國產EGFR單抗生物類似藥管線進度（I/Ⅱ期及以上）_第15頁
國產EGFR單抗生物類似藥管線進度（I/Ⅱ期及以上）_第16頁
國產EGFR單抗生物類似藥管線進度（I/Ⅱ期及以上）_第17頁
國產EGFR單抗生物類似藥管線進度（I/Ⅱ期及以上）_第18頁
國產EGFR單抗生物類似藥管線進度（I/Ⅱ期及以上）_第19頁
國產EGFR單抗生物類似藥管線進度（I/Ⅱ期及以上）_第20頁
國產EGFR單抗生物類似藥管線進度（I/Ⅱ期及以上）_第21頁
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
國產EGFR單抗生物類似藥管線進度（I/Ⅱ期及以上）_第22頁
fCDlubTku70gfCDluILlnLrop4TmqKHvvIjljYHkur/lhYPvvIkgfCBZT1nvvIgl77yJIHwKfC0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLXwKfCAyMDIyIHwgMCAgICAgICAgICAgICAgICB8IC0gICAgICAgIHwKfCAyMDIzRXwgMC41ICAgICAgICAgICAgICB8IC0gICAgICAgIHwKfCAyMDI0RXwgMSAgICAgICAgICAgICAgICB8IC0gICAgICAgIHwKfCAyMDI1RXwgNCAgICAgICAgICAgICAgICB8IC0gICAgICAgIHwKfCAyMDI2RXwgOSAgICAgICAgICAgICAgICB8IC0gICAgICAgIHwKfCAyMDI3RXwgMTQgICAgICAgICAgICAgICB8IC0gICAgICAgIHwKfCAyMDI4RXwgMTggICAgICAgICAgICAgICB8IC0gICAgICAgIHwKfCAyMDI5RXwgMjIgICAgICAgICAgICAgICB8IC0gICAgICAgIHwKfCAyMDMwRXwgMjUgICAgICAgICAgICAgICB8IC0gICAgICAgIHwKCui1hOaWmeadpea6kO+8muW8l+iLpeaWr+eJueaymeWIqeaWh++8jOWFrOWPuOaLm+iCoeivtOaYjuS5pu+8jOa1meWVhuivgeWIuOeglOeptuaJgA==
國產EGFR單抗生物類似藥管線進度（I/Ⅱ期及以上）_第23頁
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
國產EGFR單抗生物類似藥管線進度（I/Ⅱ期及以上）_第24頁
國產EGFR單抗生物類似藥管線進度（I/Ⅱ期及以上）_第25頁
國產EGFR單抗生物類似藥管線進度（I/Ⅱ期及以上）_第26頁
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
國產EGFR單抗生物類似藥管線進度（I/Ⅱ期及以上）_第27頁
國產EGFR單抗生物類似藥管線進度（I/Ⅱ期及以上）_第28頁
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
國產EGFR單抗生物類似藥管線進度（I/Ⅱ期及以上）_第29頁
國產EGFR單抗生物類似藥管線進度（I/Ⅱ期及以上）_第30頁
國產EGFR單抗生物類似藥管線進度（I/Ⅱ期及以上）_第31頁
國產EGFR單抗生物類似藥管線進度（I/Ⅱ期及以上）_第32頁
所屬報告： 科倫博泰生物~B-港股公司深度報告：國際化ADC平臺大單品商業啟航-250410（29頁）.pdf
打包全文圖表

相關數據

最新數據
聯系我們
  • 0731-84720580
  • sgpjbg002
  • 工作日 9:30 - 18:00
關于我們
侵權處理
關于我們

三個皮匠報告專業的行業報告下載站，每日更新，歡迎大家關注！

copyright@2008-2013 長沙景略智創信息技術有限公司版權所有
網站備案/許可證號：湘B2-20190120

客服
商務合作
小程序
服務號
折疊
午夜网日韩中文字幕,日韩Av中文字幕久久,亚洲中文字幕在线一区二区,最新中文字幕在线视频网站